NCT07008846Active, not recruitingPhase 3
Efficacy of Tofacitinib, Methotrexate Combination Therapy Versus Upadacitinib, Methotrexate Combination Therapy in Moderate to Severe Rheumatoid Arthritis
Source: ClinicalTrials.gov · Last updated 6 Jun 2025
Brief summary (registry, in English)
The aim of this study is to assess the efficacy of upadacitinib, methotrexate combination therapy in comparison to tofacitinib, methotrexate combination therapy in moderate to severe RA patients. This study will guide us to treat RA patients with inadequate response to methotrexate more effectively
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- First submitted
- 11 May 2025
- Start date
- 10 May 2025
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07008846
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 96
- From 10 May 2025 to the primary completion date, 30 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- 1.Recent or concurrent infection
- 2.Active or latent tuberculosis
- 3\. Hemoglobin (Hb) \< 8 g/dl 4. White blood cell count \< 4000/ micro L, Neutrophil count \< 1000/ micro L, Platelet count \< 100000/mm3 5. Live vaccines (rota virus, varicella, yellow fever) within 3 months prior to the first dose 6. Child-Pugh Class -C 7. Pregnant or planned for pregnancy and breastfeeding females of child-bearing potential 8. Evidence or history of malignancy, with the exception of adequately treated or excised non-metastatic basal or squamous cell cancer of the skin or cervical carcinoma in situ 9. New York Heart Association Class III and IV congestive heart failure 10. Previous history of thromboembolism, deep venous thrombosis, stroke, IHD
Who the study is looking for
- \- 1.Patients of both gender (age ≥18 years). 2.Patients fulfill the ACR/EULAR 2010 classification criteria for rheumatoid arthritis.
- 3.Patients with DAS-28 CRP \>3.2 despite optimum dose and duration of methotrexate (20-25 mg/week for minimum one month).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bangabandhu Sheikh Mujib Medical University Coordinator of this site? Confirm its status | Dhaka | Bangladesh | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.